STAT

JANUARY 3, 2023

A diverse and inclusive workforce benefits science and research. But unless it includes people living with a disability — the largest minority group in the U.S. and around the world — research will never be fully representative and science will not reach its full potential. Although 27% of U.S. adults live with a disability, only 10% of science, engineering, and health doctorate holders, and less than 2% of researchers funded by the National Institutes of Health, report having a di

345

345

PharmaVoice

JANUARY 3, 2023

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

279

279

pharmaphorum

JANUARY 6, 2023

Google and DeepMind have developed an artificial intelligence-powered chatbot tool called Med-PaLM designed to generate “safe and helpful answers” to questions posed by healthcare professionals and patients. The tool is an example of a large language model or LLM, which are designed to understand queries and generate text responses in plain language, drawing from large and complex datasets – in this case, medical research.

137

137

Pharmaceutical Technology

JANUARY 6, 2023

While the treatment options for multiple sclerosis (MS) patients are growing each year with the approval of new agents, all of the currently marketed treatments only slow the disease’s progression and sometimes carry risks of severe side effects, such as liver failure or the development of viral infections. However, new mechanisms of action (MoAs) are in constant development, with some of the more innovative ones utilizing cell-based therapies.

115

115

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

JANUARY 4, 2023

Continuing economic uncertainty and the threat of a recession are casting a pall over health tech in 2023 — a dramatic shift for an industry that enjoyed abundant funding in the pandemic’s early stages. Last quarter’s string of layoffs at companies like Ro, Noom and ThirtyMadison portend tight budgets and conservative contracts this year, with employers unsure about which digital offerings actually drive down health care costs for workers.

361

361

PharmaVoice

JANUARY 5, 2023

As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

246

246

Pharma Times

JANUARY 4, 2023

AstraZeneca trial will study activity of AZD5156 which includes monoclonal antibody discovered by RQ Bio

138

138

STAT

JANUARY 5, 2023

SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies to treat autoimmune diseases and cancer, is now planning to cut back on both jobs and experimental drugs after an early end to a deal with Janssen. The setback, announced Thursday, will cut the company’s size to 220 workers by the end of the first quarter of this year.

Immunity 308

Immunity Immunization 308

PharmaVoice

JANUARY 4, 2023

How charitable firms such as Advancium are helping to right the market wrongs of drug development.

Drug Development 256

Drug Development 256

pharmaphorum

JANUARY 6, 2023

From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences teams to collaborate efficiently and effectively in 2023. Veeva’s industry experts share their predictions about how breaking down silos across clinical, regulatory, safety, and quality teams will benefit patients.

Documentation 111

Documentation Drug Development Diabetes 111

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

PharmaTech

JANUARY 3, 2023

Advancing the use of AI to understand the whole of a disease can reveal drug development insights that lead to drug discovery breakthroughs.

Drug Development 122

Drug Development 122

STAT

JANUARY 6, 2023

The Food and Drug Administration on Friday approved a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease. The drug, called Leqembi, was developed by Eisai , the Japanese pharmaceutical company that also developed the first symptomatic treatment for Alzheimer’s 25 years ago.

Pharmaceutical Companies 246

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 246

PharmaVoice

JANUARY 5, 2023

Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.

246

246

European Pharmaceutical Review

JANUARY 6, 2023

The US Food and Drug Administration (FDA) has granted priority review for glofitamab, Roche’s CD20xCD3 T-cell engaging bispecific antibody. The decision for the FDA priority review of glofitamab is for adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. If approved, the cancer immunotherapy would be the first fixed-duration, off-the-shelf CD20xCD3 T-cell engaging bispecific antibody available for individuals with an aggressive

105

105

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

pharmaphorum

JANUARY 3, 2023

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year. The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months.

Labelling 105

Labelling Drug Development 105

STAT

JANUARY 3, 2023

The number of people in the United States hospitalized with Covid-19 is about to surpass the figure reached during this summer’s spike, federal data show , as a confluence of factors — from the continued evolution of the coronavirus to holiday gatherings — drives transmission. Notably, the number of people hospitalized with Covid — roughly 40,000 — is still far below the winter waves of 2020-2021 and 2021-2022 (the wave driven by the original Omicron variant) a

Hospitals 252

Hospitals 252

PharmaVoice

JANUARY 3, 2023

A preview of the top trends on the minds of industry and market leaders for the new year.

239

239

European Pharmaceutical Review

JANUARY 4, 2023

EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead Sciences, Inc, enabling EVOQ to potentially receive up $658.5 million. The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation. “Despite key advances over the past two decades, there remains significant unmet need for people living with inflammatory and autoimmune diseases,” stated Dr Flavius

Immunization 105

Immunization Immunity 105

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JANUARY 3, 2023

Research advises against aggressive cancer treatment at the end-of-life stages of the disease. At the same time, the pharmaceutical industry is creating a greater number of oncology treatments that could provide breakthroughs for patients where none previously existed. Ben Hargreaves examines why there is no easy answer to the question of when palliative care is the right option for patients.

Chemotherapy 105

Chemotherapy Immunization Immunity Hospitals 105

STAT

JANUARY 3, 2023

If rebates had been required for price hikes on most of the nearly 100 medicines covered by Medicare during a recent three-year period, the U.S. government program would have saved $3.7 billion, or 3% of the total spending on so-called Part B medicines, a new analysis found. More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would

Immunity 246

Immunity Immunization Hospitals Drug Pricing 246

PharmaVoice

JANUARY 4, 2023

The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.

130

130

PharmExec

JANUARY 6, 2023

A chat with with Indegene's Timothy Moore, Senior Vice President, Emerging Biotech and Key Accounts and Jack Mycka, Vice President, Enterprise Medical Solutions and Emerging Biotech.

98

98

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

pharmaphorum

JANUARY 6, 2023

With the US economy teetering on a recession, sales and marketing budgets are expected to take a hit among businesses across sectors. The pharmaceutical industry is no exception. When any organisation looks to slash its budget, the old adage about acquiring new customers costing five times as much as retaining existing customers becomes an alluring data point.

Diabetes 105

Diabetes Pharmaceutical Companies Pharmaceutical Companies 105

STAT

JANUARY 3, 2023

As inflation-weary shoppers try to make ends meet, many are turning to a modern twist on the layaway plan: buy now, pay later. But while platforms like Afterpay and Affirm were originally built to take the sting out of online shopping, these new financing options are beginning to creep into the world of health care. “Buy now, pay later is a small fraction of the health space, but it is exploding,” said Jay Zagorksy, an economist at the Questrom School of Business at Boston Universi

246

246

PharmaVoice

JANUARY 6, 2023

Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

130

130

Board Vitals - Pharmacist

JANUARY 2, 2023

The Internal Medicine Board Certification Exam is the final step for doctors looking to specialize in Internal Medicine. This in-depth exam covers a range of different topics, including Hematology, Psychiatry, and Dermatology. Passing the boards is not a guarantee, but with the right plan in place, you will be confident and prepared come test day. What is the Internal Medicine Board Exam?

Nursing Homes 98

Nursing Homes Inpatient Hospitals 98

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

European Pharmaceutical Review

JANUARY 6, 2023

GSK will exclusively license up to four bi- and multi-specific T cell engaging (TCE) antibodies developed using technology platforms from WuXi Biologics, a contract research, development, and manufacturing organisation (CRDMO). Licensing T cell engaging antibodies. The CRDMO will receive a $40 million upfront payment from GSK and up to $1.46 billion in additional payments for research, development , regulatory and commercial milestones across the four TCE antibodies.

98

98

STAT

JANUARY 6, 2023

The Environmental Protection Agency announced on Friday more aggressive air quality standards for particulate matter, pollutants small enough to be inhaled and cause respiratory illness and other disease. The agency’s new rules would help clean the nation’s air and bring it more in line with the past decade of research on the harmful effects of particulate matter.

246

246

Med Ed 101

JANUARY 1, 2023

Opioids are commonly used in clinical practice. Selection on these agents can often be confusion. We’ve outlined some of the most important pharmacokinetic, pharmacogenomic, and dosage form clinical pearls in the table below. For easier reading, we have also created the Opioid Comparison Table as a free downloadable PDF which you can download at the […].

Dosage 98

Dosage 98

pharmaphorum

JANUARY 4, 2023

More than 30 years after it was first formed, Geron is on the cusp of bringing its first product to market, after imetelstat hit the mark in a phase 3 trial in patients with myelodysplastic syndromes (MDS). The Foster City, California-based biotech said today that its IMerge trial of imetelstat – vying to become the first telomerase inhibitor to reach the market – hit its objectives in patients with lower risk MDS, a rare group of bone marrow cancers.

98

98

European Pharmaceutical Review

JANUARY 3, 2023

A marketing authorisation application (MAA) has been submitted by The Janssen Pharmaceutical Companies of Johnson & Johnson to the European Medicines Agency (EMA) for approval of talquetamab, a bispecific t-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf treatment targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and CD3 on t-cell

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98